Communiqués Immatics N.V.

Actions

IMTX

NL0015285941

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 17:50:05 09/07/2026			Varia. 5j.	Varia. 1 janv.
9,845 ^USD	-1,35%		-1,11%	-6,29%

01/06	Immatics N.V. publie des données cliniques actualisées pour ses thérapies cellulaires PRAME IMA203CD8, IMA401 et Anzu-Cel	CI
01/06	Immatics présente l'activité clinique et la dynamique de réponse de la thérapie cellulaire Anzu-Cel (PRAME) au congrès annuel de l'ASCO 2026	CI

Communiqués

01/06	Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting	GL
31/05	Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer	GL
31/05	Immatics N : 2026 ASCO Immatics #11516 anzu-cel IMA203CD8 SynovialSarcoma	PU
30/05	Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting	GL
12/05	Immatics: Q1 Earnings Snapshot	AQ
12/05	Immatics Announces First Quarter 2026 Financial Results and Business Update	GL
21/04	Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting	GL
17/04	Immatics N : PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma	PU
17/04	PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma	GL
05/03	Immatics: Q4 Earnings Snapshot	AQ
05/03	Immatics Announces Full Year 2025 Financial Results and Business Update	GL
11/12	Immatics N : 251211 IMTX IMA203CD8 ESMO-IO FINAL	PU
11/12	Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress	GL
05/12	Immatics Announces $125 Million Underwritten Offering	GL
17/11	Immatics: Q3 Earnings Snapshot	AQ
17/11	Immatics Announces Third Quarter 2025 Financial Results and Business Update	GL
12/11	Immatics N : 251010 TCER Data Release Nov 2025	PU
12/11	Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps	GL
27/10/25	Immatics N : 251027 SMR TiP Poster SUPRAME Anzu-cel Phase 3 Trial in Advanced Cutaneous Melanoma	PU
27/10/25	Immatics Appoints Amie Krause as Chief People Officer	GL
20/10/25	Immatics N : 251020 ESMO Anzu-cel Uveal Melanoma Presentation FINAL	PU
20/10/25	Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium	GL
01/10/25	Immatics Appoints Venkat Ramanan as Chief Financial Officer	GL
13/08/25	Immatics: Q2 Earnings Snapshot	AQ
13/08/25	Immatics Announces Second Quarter 2025 Financial Results and Business Update	GL